$5.19
▲ +0.8% Today
as of Sep 4, 16:45 ET
Last 30 days
Recent Press Releases & News
Arbutus Biopharma Launches $230 Million Tender Offer for Common Shares
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan
Overview
52-week range
$3.50
$5.45
87% of range
Avg surprise (last 2)
+52.8%
Avg reaction (last 2)
-0.5%
0% positive
Latest IV / EM
43%
EM ±6.8% · $5 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.03 | — | — | — | — | financials |
| Wed May 13, 2026 | Mar/2026 | $0.87 | — | — | +769.2% | 0.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.04 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $0.01 | $-0.02 | +150.0% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.13 | $-0.09 | -44.4% | — | -0.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.10 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.11 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.10 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.12 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.10 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.10 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $179M | — | $529,000 | $11M | $2M | — | $1M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-6M | $169M | — | $-9M | $1M | $-26M | — | $-21M |
| Net income | $-5M | $170M | — | $-8M | $3M | $-25M | — | $-20M |
| EPS (diluted) | $-0.03 | $0.87 | — | $-0.04 | $0.01 | $-0.13 | — | $-0.10 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $19M | $24M | $18M | $22M | $37M | $37M | $36M | $32M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $274M | $277M | $94M | $97M | $103M | $117M | $127M | $133M |
| Total assets | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M |
| Long-term debt | $0 | $0 | — | $0 | $0 | $0 | — | $0 |
| Total liabilities | $15M | $17M | $18M | $20M | $20M | $38M | $34M | $34M |
| Total equity | $259M | $260M | $77M | $77M | $83M | $79M | $97M | $107M |